| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| 99213 |
Office or other outpatient visit for the evaluation and management of an established patient, low complexity |
4,331 |
3,936 |
$462K |
| 99214 |
Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity |
3,152 |
2,938 |
$438K |
| 87636 |
Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B |
1,059 |
1,047 |
$151K |
| 99394 |
Periodic comprehensive preventive medicine reevaluation, established patient, adolescent (12-17 years) |
797 |
797 |
$110K |
| 99393 |
Periodic comprehensive preventive medicine reevaluation, established patient, late childhood (5-11 years) |
801 |
801 |
$101K |
| 99392 |
Periodic comprehensive preventive medicine reevaluation, established patient, early childhood (1-4 years) |
384 |
384 |
$49K |
| 90460 |
Immunization administration through 18 years of age via any route, first or only component |
2,168 |
2,123 |
$39K |
| 87651 |
Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe |
632 |
623 |
$22K |
| U0003 |
Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r |
209 |
206 |
$16K |
| 87631 |
|
59 |
59 |
$8K |
| 80050 |
General health panel |
192 |
192 |
$8K |
| 87880 |
Infectious agent antigen detection by immunoassay; Streptococcus, group A |
493 |
487 |
$8K |
| 87804 |
Infectious agent antigen detection by immunoassay; Influenza, each type |
198 |
197 |
$6K |
| 96127 |
|
959 |
958 |
$6K |
| 87591 |
Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe |
153 |
153 |
$5K |
| 87491 |
Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe |
153 |
153 |
$5K |
| U0005 |
Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 |
186 |
183 |
$5K |
| 99383 |
|
28 |
28 |
$4K |
| 87070 |
|
357 |
355 |
$3K |
| 99441 |
|
48 |
46 |
$3K |
| 80061 |
Lipid panel |
173 |
173 |
$2K |
| 99384 |
|
14 |
14 |
$2K |
| 83036 |
Hemoglobin; glycosylated (A1C) |
185 |
185 |
$2K |
| 99391 |
Periodic comprehensive preventive medicine reevaluation, established patient, infant (under 1 year) |
13 |
13 |
$2K |
| 99442 |
|
14 |
14 |
$1K |
| 90686 |
|
911 |
911 |
$676.94 |
| 92551 |
|
745 |
742 |
$464.07 |
| 83655 |
|
28 |
28 |
$336.56 |
| 90716 |
|
57 |
57 |
$153.87 |
| 36415 |
Collection of venous blood by venipuncture |
138 |
136 |
$117.00 |
| 85018 |
|
34 |
34 |
$80.02 |
| 96160 |
|
728 |
727 |
$46.37 |
| 90715 |
|
27 |
27 |
$45.31 |
| 90651 |
|
95 |
95 |
$0.00 |
| 36416 |
|
35 |
35 |
$0.00 |
| 90633 |
|
63 |
63 |
$0.00 |
| 90734 |
|
122 |
122 |
$0.00 |
| 90670 |
|
40 |
40 |
$0.00 |
| 99173 |
|
165 |
165 |
$0.00 |